Gender differences in pharmacokinetics of maintenance dosed buprenorphine

Drug and Alcohol Dependence

Volumn 118, Issue 2-3, 2011, Pages 479-483

  Moody, David E ^a   Fang, Wenfang B ^a   Morrison, Jerdravee ^a   McCance Katz, Elinore ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Buprenorphine metabolism; Buprenorphine pharmacokinetics; Buprenorphine 3 glucuronide; Gender differences; Norbuprenorphine; Norbuprenorphine 3 glucuronide

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CYTOCHROME P450 3A; NORBUPRENORPHINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN; LEAN BODY WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; OPIATE ADDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BUPRENORPHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTICS; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS;

EID: 80053570710     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.03.024     Document Type: Article

References (40)

1. Baker J., Rainey P.M., Moody D.E., Morse G.D., Ma Q., McCance-Katz E.F. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine and tenofovir. Am. J. Addict. 2010, 19:17-29.
2. Bruce R.D., McCance-Katz E., Kharasch E.D., Moody D.E., Morse G.D. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin. Infect. Dis. 2006, 43(Suppl. 4):S216-S223.
3. Chang Y., Moody D.E. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab. Lett. 2009, 3:101-107.
4. Chang Y., Moody D.E., McCance-Katz E.F. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos. 2006, 34:440-448.
5. Cone E.J., Gorodetzky C.W., Yousefnejad D., Buchwald W.F., Johnson R.E. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 1984, 12:577-581.
6. Cowan A., Lewis J.W., MacFarlane I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 1977, 60:537-545.
7. Franconi F., Brunelleschi S., Steardo L., Cuomo V. Gender differences in drug response. Pharmacol. Res. 2007, 55:81-95.
8. Gandhi M., Aweeka F., Greenblatt R.M., Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. Annu. Rev. Pharmacol. Toxicol. 2004, 44:499-523.
9. Hallynck T.H., Soep H.H., Thomis J.A., Boelaert J., Daneels R., Dettli L. Should clearance be normalized to body surface area or to lean body mass?. Br. J. Clin. Pharmacol. 1981, 11:523-526.
10. Hu Z.Y., Zhao Y.S. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. Drug Metab. Dispos. 2010, 38:817-823.
11. Huang W., Moody D.E., McCance-Katz E.F. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther. Drug Monit. 2006, 28:245-251.
12. Iribarne C., Picart D., Dreano Y., Bail J.-P., Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver micrsomes. Life Sci. 1997, 60:1953-1964.
13. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadol acetate, buprenorphine and methadone for opioid dependence. N. Engl. J. Med. 2000, 343:1290-1297.
14. Kintz P. Deaths involving buprenorphine: a compendium of cases. Forensic Sci. Int. 2001, 121:65-69.
15. Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada N., Ishizaki T., Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 1998, 26:818-821.
16. Lamba V., Panetta J.C., Strom S., Schuetz E. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J. Pharm. Exp. Ther. 2010, 332:1088-1099.
17. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998, 93:475-486.
18. McCance-Katz E.F. Office-based buprenorphine treatment for opioid-dependent patients. Harv. Rev. Psychiatry 2004, 12:321-338.
19. McCance-Katz E.F., Moody D.E., Morse G.D., Friedland G., Pade P., Baker J., Alvanzo A., Smith P., Ogundele A., Jatlow P., Rainey P.M. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin. Infect. Dis. 2006, 43(Suppl. 4):S224-S234.
20. McCance-Katz E.F., Moody D.E., Morse G.D., Ma Q., DiFrancesco R., Friedland G., Pade P., Rainey P.M. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007, 91:269-278.
21. McCance-Katz E.F., Moody D.E., Morse G.D., Ma Q., Rainey P.M. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am. J. Addict. 2010, 19:30-37.
22. McCance-Katz E.F., Moody D.E., Smith P.F., Morse G.D., Friedland G., Pade P., Baker J., Alvanzo A., Jatlow P., Rainey P.M. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin. Infect. Dis. 2006, 43(Suppl. 4):S235-S246.
23. McCance-Katz E.F., Rainey P.M., Moody D.E. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am. J. Addict. 2010, 19:38-46.
24. Moody D.E., Chang Y., Huang W., McCance-Katz E.F. The in vivo response of novel buprenorphine metabolites. M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin. Pharmacol. Toxicol. 2009, 105:211-215.
25. Moody D.E., Fang W.B., Lin S.N., Weyent D.M., Strom S.C., Omiecinski C.J. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. Drug Metab. Dispos. 2009, 37:2323-2329.
26. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., Foltz R.L. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 2002, 306:31-39.
27. Mosteller R.D. Simplified calculation of body-surface area. N. Engl. J. Med. 1987, 317:1098.
28. Parkinson A., Mudra D.R., Johnson C., Dwyer A., Carroll K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 2004, 199:193-209.
29. Picard N., Cresteil T., Djebli N., Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos. 2005, 33:689-695.
30. Pirnay S., Borron S.W., Giudicelli C.P., Tourneau J., Baud F.J., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004, 99:978-988.
31. Rouguieg K., Picard N., Sauvage F.L., Gaulier J.M., Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab. Dispos. 2010, 38:40-45.
32. Schottenfeld R.S., Pakes J.R., Kosten T.R. Prognostic factors in buprenorphine-versus methadone-maintained patients. J. Nerv. Ment. Dis. 1998, 186:35-43.
33. Soldin O.P., Mattison D.R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 2009, 48:143-157.
34. Unger A., Jung E., Winklbaur B., Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J. Addict. Dis. 2010, 29:217-230.
35. United States Food and Drug Administration Guidelines for the study and evaluation of gender differences in the clinical evaluation of drugs. Fed. Regist. 1993, 58:39406-39416.
36. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharm. Ther. 1994, 55:569-580.
37. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol. 2009, 76:215-228.
38. World Health Organization, 2002. Gender disparities in mental health. Available from: (accessed 26.11.10). http://www.who.int/mental_health/media/en/242.pdf.
39. Williams L.R., Leggett R.W. Reference values for resting blood flow to organs of man. Clin. Phys. Physiol. Meas. 1989, 10:187-217.
40. Yang X., Zhang B., Molony C., Chudin E., Hao K., Zhu J., Gaedigk A., Suver C., Zhong H., Leeder J.S., Guengerich F.P., Strom S.C., Schuetz E., Rushmore T.H., Ulrich R.G., Slatter J.G., Schadt E.E., Kasarskis A., Lum P.Y. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010, 20:1020-1036.